Journals / Anadolu Kardiyoloji Dergisi / 2009 / Cilt: 9 - Sayı: 4

İki östrojen reseptör-α gen polimorfizminin anjiyografik koroner arter hastalığı ile olan ilişkisi

Relationship between two estrogen receptor-α gene polymorphisms and angiographic coronary artery disease

Pages
267–272
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Further confirmation of these findings is required.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Ob­jec­ti­ve: To investigate the association of estrogen receptor-α PvuII and BtgI polymorphisms with angiographic presence and severity of coronary artery disease (CAD).
📊
Key Findings & Data:Methods: Our cross-sectional study included 140 patients with ≥50% coronary stenoses (CAD group) and 47 patients with normal angiograms (CAD-free group) (total n=187, age 59.6±13.2 years; 66 women).
💡
Conclusion & Impact:Further confirmation of these findings is required.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Ob­jec­ti­ve: To investigate the association of estrogen receptor-α PvuII and BtgI polymorphisms with angiographic presence and severity of coronary artery disease (CAD). Methods: Our cross-sectional study included 140 patients with ≥50% coronary stenoses (CAD group) and 47 patients with normal angiograms (CAD-free group) (total n=187, age 59.6±13.2 years; 66 women). PvuII and BtgI genotype and allele distributions were determined by standard method of polymerase chain reaction and restriction fragment length polymorphism. The CAD subgroups by the number of diseased vessels were also defined. Variable associations and group differences were analyzed by independent t test, one-way ANOVA, Pearson's Chi-square (χ2), Spearman’s correlation tests and logistic regression analyses.Results: While there was no association between PvuII polymorphism and angiographic CAD (p=0.384), BtgI polymorphism was more prevalent in CAD-free group (23.4% vs. 10% (CAD group), OR=2.75, 95% CI=1.150 to 6.579, p=0.019). This difference was more pronounced in women (28.6% vs. 4.4%; OR=8.6; 95% CI=1.564 to 47.303; p=0.005) compared to men (p=0.391). Logistic regression analysis confirmed BtgI polymorphism as the most important predictor for a normal coronary angiogram among parameters such as body mass index, diabetes and age (OR 8.13, 95% CI 1.257 to 52.627, p=0.028). However, no significant association between BtgI polymorphism and the number of stenotic arteries was detected.Conclusion: ESR1 PvuII polymorphism is not associated with angiographically significant CAD. ESR1 BtgI polymorphism is strongly associated with the presence of normal coronary angiograms in women, which suggests protective effect. Further confirmation of these findings is required.

Özet

Amaç: Östrojen reseptör-α PvuII and BtgI gen polimorfizmlerinin koroner arter hastalığının (KAH) anjiyografik varlığı ve şiddeti ile olan ilişkisinin incelenmesi.Yöntemler: Enine-kesitli olan çalışmamızda, anjiyografisinde %50 ve üzeri koroner arter stenozu bulunan 140 hasta (KAH grubu) ile koroner anjiyogramı normal olan 47 hasta (KAH olmayan grup) olmak üzere toplam 187 hasta incelendi (yaş ortalaması 59.6±13.2 yıl; 66’sı kadın). PvuII ve BtgI genotipleri polimeraz zincir reaksiyonu ve “restriction fragment length polymorphism” yöntemleri yardımı ile saptandı. Koroner arter hastalığı şiddeti hastalıklı damar sayısına göre derecelendirildi. Değişkenler arası bağıntılar ve gruplar arası farklar bağımsız t testi, tek-yönlü ANOVA, Pearson Ki-kare (χ2), Spearman korelasyon testleri ve lojistik regresyon analizleri ile incelendi.Bulgular: Grupların karşılaştırılmasında PvuII polimorpfizmi ile anjiyografik KAH arasında herhangi bir anlamlı ilişki bulunmazken (p=0.219), BtgI polimorfizminin KAH olmayan grupta daha sık görüldüğü tespit edildi (%23.4’e karşı %10 (KAH), OR=2.75, %95 GA=1.15 - 6.58, p=0.019). Alt grup analizinde bu farkın erkeklerden ziyade (p=0.391) asıl olarak kadınlarda görüldüğü saptandı (%28.6’ya karşı %4.4 (KAH); OR=8.6; %95 GA=1.564 - 47.303; p=0.005). Lojistik regresyon analizinde BtgI polimorfizminin vücut kitle indeksi, yaş ve diyabet gibi yan değişkenlere göre normal koroner anjiyogram sonucunu kestirme bakımından daha güçlü bir değişken olduğu teyit edildi (OR 8.13, %95 GA 1.257-52.627, p=0.028). Ancak, BtgI polimorfizmi ile KAH şiddeti arasında anlamlı bir ilişki saptanmadı.Sonuç: Östrojen reseptör-α PvuII polimorfizmi ile anjiyografik KAH arasında bir bağıntı saptanmazken özellikle kadınlarda BtgI polimorfizmi ile KAH arasında güçlü bir ters ilişki bulunmaktadır. BtgI polimorfizminin kadınlarda KAH'na karşı koruyucu etkisinin olabileceğini gösteren bu bulguların başka çalışmalarda da teyit edilmesi gereklidir.

🔖

Cite This Article

GÜVEN, M., ULUTİN, T., BATAR, B., ÖZ, E., HACIOĞLU, Y., DOMANİÇ, N., VURAL, A. V., KARADAĞ, B. (2022). İki östrojen reseptör-α gen polimorfizminin anjiyografik koroner arter hastalığı ile olan ilişkisi. Anadolu Kardiyoloji Dergisi, Cilt: 9 - Sayı: 4, 267–272. https://ajindex.com/articles/436889

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Pepine CJ, Kerensky RA, Lambert CR, Smith KM, von Mering GO, Sopko G, et al. Some thoughts on the vasculopathy of women with ischemic heart disease. J Am Coll Cardiol 2006; 47: S30-5
  2. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Eng J Med 1999; 340: 1801-11
  3. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg G, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33
  4. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605-13
  5. Sudhir K, Chou TM, Chatterjee K, Smith EP, Williams TC, Kane JP, et al. Premature coronary artery disease associated with disruptive mutation in estrogen receptor gene in a man. Circulation 1997; 96: 3774-7
  6. Sudhir K, Chou TM, Messina LM, Hutchison S, Korach K, Chatterjee K, et al. Endothelial dysfunction in a man with disruptive mutation in estrogen-receptor gene. Lancet 1997; 349: 1146-7
  7. Cowley SM, Hoare S, Mosselman S, Parker MG. Estrogen receptors alpha and beta form heterodimers on DNA. J Biol Chem 1997; 272: 19858-62
  8. Shearman AM, Cupples LA, Demissie S, Peter I, Schmid CH, Karas RH, et al. Association between estrogen receptor alpha gene variation and cardiovascular disease. JAMA 2003; 290: 2263-70
  9. Schuit SC, Oei HH, Witteman JC, Geurts van Kessel CH, van Meurs JB, Nijhuis RL, et al. Estrogen Receptor {alpha} Gene Polymorphisms and Risk of Myocardial Infarction. JAMA 2004; 291: 2969-77
  10. Koch W, Hoppmann P, Pfeufer A, Mueller JC, Schömig A, and Kastrati A. No replication of association between estrogen receptor gene polymorphisms and susceptibility to myocardial Infarction in a large sample of patients of European descent. Circulation 2005; 112: 2138-42
  11. Kjaergaard AD, Ellervik C, Tybjaerg-Hansen A, Axelsson CK, Grønholdt ML, Grande P, et al. Estrogen receptor alpha polymorphism and risk of cardiovascular disease, cancer, and hip fracture: cross-sectional, cohort, and case-control studies and a meta-analysis. Circulation 2007; 115: 861-71
  12. Colson NJ, Lea RA, Quinlan S, MacMillan J, and Griffiths L. The estrogen receptor 1 G594A polymorphism is associated with migraine susceptibility in two independent case/control groups. Neurogenetics 2